Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xoma Royalty Corporation (NQ: XOMA )

25.86 +0.18 (+0.70%)
Streaming Delayed Price Updated: 3:49 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18,567
Open 25.94
Bid (Size) 25.90 (3)
Ask (Size) 26.20 (5)
Prev. Close 25.68
Today's Range 25.64 - 26.46
52wk Range 13.48 - 27.36
Shares Outstanding 11,625,826
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21. 
Via Benzinga
Exposures Product Safety
Demystifying XOMA: Insights From 5 Analyst Reviews
Via Benzinga

Performance

YTD
+23.79%
+23.79%
1 Month
+11.03%
+11.03%
3 Month
+0.31%
+0.31%
6 Month
+24.57%
+24.57%
1 Year
+53.11%
+53.11%

More News

Read More
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
From XOMA Corporation
Via GlobeNewswire
Peeling Back The Layers: Exploring XOMA Through Analyst Insights
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For XOMA
Via Benzinga
Recap: XOMA Q4 Earnings
Via Benzinga
3 Crazy Good Stocks to Buy With $500 Right Now
Via InvestorPlace
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
From XOMA Corporation
Via GlobeNewswire
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
From XOMA Corporation
Via GlobeNewswire
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
From XOMA Corporation
Via GlobeNewswire
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
From XOMA Corporation
Via GlobeNewswire
XOMA Corporation Announces Closing of Tender Offer
From XOMA Corporation
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
From Brodsky & Smith LLC
Via GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
From XOMA Corporation
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)
From Brodsky & Smith LLC
Via GlobeNewswire
XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
From XOMA Corporation
Via GlobeNewswire
XOMA to Present at Upcoming Investor Conferences in March
From XOMA Corporation
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)
From Brodsky & Smith LLC
Via GlobeNewswire
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
Via Benzinga
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
From XOMA Corporation
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.